Advanced Search

    column
    Opportunities and Challenges of New Treatment Strategy in Non-Small Cell Lung Cancer
    LI An-na, JIANG Ben-yuan, XU Chong-rui, YANG Xue-ning, YANG Jin-ji, WU Yi-long
    2025, 25(1): 1-18. DOI: 10.12019/j.issn.1671-5144.202502031
    Abstract PDF
    Second-Line Therapy for Advanced NSCLC Patients With Negative Oncogenic Driver Mutation: Chemotherapy Remain on the Board
    REN Sheng-xiang
    2025, 25(1): 19-20. DOI: 10.12019/j.issn.1671-5144.202502001
    Abstract PDF
    The Bispecific T-Cell Engager Tarlatamab Made a Breakthrough in Extensive Stage Small-Cell Lung Cancer
    WANG Yong-sheng
    2025, 25(1): 21-22. DOI: 10.12019/j.issn.1671-5144.202502005
    Abstract PDF
    HARMONi-A Study: A New Pathway for Treatment Among EGFR-Mutated NSCLC
    LIN Gen
    2025, 25(1): 23-23. DOI: 10.12019/j.issn.1671-5144.202502007
    Abstract PDF
    Clinical Efficacy, Immune Response, and Safety of NK Cell Therapy in Advanced Non-Small Cell Lung Cancer: A Preliminary Study
    LI Zi-ming
    2025, 25(1): 24-24, 26. DOI: 10.12019/j.issn.1671-5144.202502012
    Abstract PDF
    Efficacy and Safety of Gefitinib Combined with Allogeneic CD8+ NKT Cell Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    DONG Xiao-rong
    2025, 25(1): 25-26. DOI: 10.12019/j.issn.1671-5144.202502014
    Abstract PDF
    Amivantamab Combined With Lazertinib Opens a New Pattern of Treatment for Advanced NSCLC With EGFR Mutation
    ZHANG Chan-yuan, FENG Wei-neng
    2025, 25(1): 27-30. DOI: 10.12019/j.issn.1671-5144.202502013
    Abstract PDF
    Bispecific Antibody-Drug Conjugate May Become a Potential Treatment Choice for Patients With Advanced NSCLC
    LIU Yu-tao
    2025, 25(1): 31-31. DOI: 10.12019/j.issn.1671-5144.202502018
    Abstract PDF
    SUVmax After Neoadjuvant Therapy as a Prognostic Marker forOperable Non-Small Cell Lung Cancer
    LIN Jun-tao, SUN Ming, YE Kai-yan, GUO Hao, LIU Si-yang, HOU Qing-yi, LIAO Ri-qiang, NIE Qiang, DONG Song, JIANG Ben-yuan, ZHONG Wen-zhao, WU Yi-long, YANG Xue-ning
    2025, 25(1): 32-41. DOI: 10.12019/j.issn.1671-5144.202410021
    Abstract PDF
    Clinical Features and Prognostic Factors of 84 Patients With Extranodal Natural Killer/T Cell Lymphoma
    SHI Qiong, NIE Lin-lin, HUANG Zi-qing, XU Bing, ZHU Feng
    2025, 25(1): 42-54, 64. DOI: 10.12019/j.issn.1671-5144.202410042
    Abstract PDF
    Analysis of Efficacy of First-Line Chemotherapy Combined With Immunotherapy for Non-Small Cell Lung Cancer Patients With Different Mutation Subtypes of KRAS
    HAO Yue, WANG Ke, WANG Qian, WANG Dong, XU Chun-wei, SONG Zheng-bo, SONG Yong, LV Tang-feng
    2025, 25(1): 55-64. DOI: 10.12019/j.issn.1671-5144.202411027
    Abstract PDF